She's not a wild-eyed fanatic screaming from a soapbox; she's a well-spoken, educated woman who happens to believe that ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

The British drug agency is monitoring a possible increase in cases of the disease, although there is no data yet to warrant ...